Guidance

Post exposure prophylaxis for chickenpox and shingles

Post exposure prophylaxis (PEP) is offered to individuals at high risk of severe chickenpox following an exposure.

From:
UK Health Security Agency
Published
27 April 2022
Last updated
7 October 2024 — See all updates

Applies to England

Documents

Guidelines on post exposure prophylaxis (PEP) for varicella or shingles (October 2024)

HTML

Varitect CP (VZIg) request form

MS Excel Spreadsheet, 120 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Post exposure prophylaxis (PEP) is offered to individuals at high risk of severe chickenpox following an exposure. This includes pregnant women, immunosuppressed individuals, and susceptible neonates.

As VZIG is no longer available in the UK, for neonates designated in Group 1 i.e. those exposed to their mother (in utero or post-delivery) within one week of onset of chicken pox in the mother, the antiviral treatment should be supplemented with intravenous (i.v.) varicella immunoglobulin either as a hyperimmune product (i.e. Varitect CP) (which can be obtained via the Duty Doctor/RIGS team in the same way that VZIG was (UK Health Security Agency (UKHSA) Rabies and Immunoglobulin Service (RIgS)) or normal intravenous immunoglobulin (IVIG) ( which NHS trusts will have ready access to).

A bolus dose of IVIG may also be considered for eligible groups for whom oral antivirals are contraindicated

The detailed guidance above should be used to assess those at high risk.

Updates to this page

Published 27 April 2022
Last updated 7 October 2024 + show all updates

  1. Updated to version 5.0 including how to source Varitect CP in England and updated information on timings of post-exposure prophylaxis. Added new Varitect (VZig) clinical record and Movianto request form.

  2. Updated the guidance and converted it to HTML.

  3. Updated form.

  4. Updated 'Varicella zoster immunoglobulin clinical record form'.

  5. Updated guidance, see page 3 for changes.

  6. First published.

Sign up for emails or print this page

Related content